For Healthcare Professionals

A Study to Investigate RO7200220 in Diabetic Macular Edema


About the study

Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7200220 administered intravitreally in participants with diabetic macular edema. Only one eye will be chosen as the study eye. The duration of the study will be up to 76 weeks.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Diagnosis of diabetes mellitus (Type 1 or Type 2)
  2. Macular thickening secondary to diabetic macular edema (DME) involving the center of the macula
  3. Decreased visual acuity attributable primarily to DME
  4. Ability and willingness to provide written informed consent and to comply with the study protocol
  5. Willingness to allow Aqueous Humor collection
  6. For women of childbearing potential: agreement to remain abstinent or use at least one highly effective contraceptive method that results in a failure rate of <1% per year during the treatment period and for at least 12 weeks after the final dose of study treatment


Exclusion Criteria:

  1. Hemoglobin A1c (HbA1c) of greater than (>) 12%
  2. Uncontrolled blood pressure, defined as a systolic value greater than (>)180 millimeters of mercury (mmHg) and/or a diastolic value >100 mmHg while a patient is at rest
  3. Currently pregnant or breastfeeding, or intend to become pregnant during the study
  4. Prior treatment with panretinal photocoagulation or macular laser to the study eye
  5. Any intraocular or periocular corticosteroid treatment within the past 16 weeks prior to Day 1 to the study eye
  6. Prior Iluvien or Retisert implants within 3 years prior to Day 1 to the study eye
  7. Prior or concomitant treatment with anti-VEGF therapy within 8 weeks prior to Day 1 to the study eye; Vabysmo^TM within 16 weeks prior to Day 1, prior Beovu® is not permitted
  8. Prior administration of IVT brolucizumab (Beovu®): ever; RO7200220:
  9. Any proliferative diabetic retinopathy
  10. Active intraocular or periocular infection or active intraocular inflammation in the study eye
  11. Any current or history of ocular disease other than DME that may confound assessment of the macula or affect central vision in the study eye
  12. Any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than DME in the study eye
  13. Other protocol-specified inclusion/exclusion criteria may apply

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Diabetic Macular Edema

Age (in years)



Phase 2

Participants needed


Est. Completion Date

Apr 17, 2025

Treatment type



Hoffmann-La Roche identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.